NGNE · XBRL financial data

Neurogene financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NGNE's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	—	—	—	0	925	0
Research and development	—	39,162	41,129	44,394	60,917	75,011
General and administrative	17,210	21,536	17,968	11,189	22,613	28,317
Total operating expenses	—	60,698	59,097	55,583	83,530	103,328
Operating income (loss)	(33,728)	(60,698)	(59,097)	(55,583)	(82,605)	(103,328)
Interest income	—	—	1,337	2,951	8,467	11,547
Interest expense	—	—	2	12	12	5
Other income (expense)	(44)	(12)	—	—	—	—
Income tax expense (benefit)	—	—	—	—	0	0
Net income (loss)	(33,277)	(60,692)	(57,557)	(36,317)	(75,144)	(90,351)
Earnings per share, basic‡ USD per share	(12.80)	(22.00)	(20.80)	—	(4.28)	(4.24)
Earnings per share, diluted‡ USD per share	(12.80)	(22.00)	(20.80)	—	(4.28)	(4.24)
Weighted average shares, basic‡ thousands of shares	2,591	2,752	2,761	—	17,567	21,326
Weighted average shares, diluted‡ thousands of shares	2,591	2,752	2,761	—	17,567	21,326

‡ Per-share figures and share counts are adjusted for the 1-for-5 stock split (September 2023); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-4 stock split (December 2023); filings made before it reported them unadjusted.
† Share count changed about 6x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (NGNE's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	192,556	142,467	37,887	148,210	136,586	103,845
Short-term investments	—	0	58,497	48,947	175,819	165,168
Marketable securities	—	0	58,497	—	—	—
Prepaid and other current assets	—	—	2,698	3,191	3,518	2,757
Total current assets	194,522	143,989	99,134	200,348	315,923	271,770
Property and equipment, net	3,570	6,452	20,115	17,174	15,422	12,792
Right-of-use asset	10,154	10,766	9,715	3,681	3,000	2,648
Total assets	210,519	163,263	115,948	222,573	335,730	288,604
Accounts payable	—	—	625	2,596	1,336	1,953
Accrued liabilities	—	—	5,324	17,495	9,731	10,756
Total current liabilities	7,889	8,636	11,062	22,973	15,157	16,411
Lease liability, non-current	11,306	11,696	10,322	12,302	9,403	6,822
Total liabilities	19,303	20,399	21,617	36,549	25,355	23,717
Accumulated deficit	(332,806)	(393,498)	(451,055)	(187,154)	(262,298)	(352,649)
Total stockholders' equity	191,216	142,864	94,331	186,024	310,375	264,887
Total liabilities and equity	210,519	163,263	115,948	222,573	335,730	288,604
Common shares outstanding (cover page)‡ thousands of shares	2,116	2,125	2,141	12,853	14,930	15,574

‡ Per-share figures and share counts are adjusted for the 1-for-5 stock split (September 2023); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-4 stock split (December 2023); filings made before it reported them unadjusted.
† Share count changed about 6x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (NGNE's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(33,277)	(60,692)	(57,557)	(36,317)	(75,144)	(90,351)
Stock-based compensation	5,622	11,557	8,829	1,418	8,320	14,183
Depreciation and amortization	785	1,306	1,561	3,262	3,195	3,043
Net cash from operating activities	(24,575)	(47,558)	(45,607)	(51,422)	(70,603)	(77,173)
Purchases of property and equipment	2,219	3,263	1,110	321	808	1,183
Net cash from investing activities	(2,219)	(3,263)	(59,134)	25,637	(125,261)	14,004
Proceeds from issuing common stock	71,675	0	0	92,343	0	30,380
Net cash from financing activities	77,135	732	161	92,482	184,071	30,428
Net change in cash	50,341	(50,089)	(104,580)	66,697	(11,793)	(32,741)

† Share count changed about 6x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Neurogene	112,485	not reported	(23,761)*	20.0M	9.5 quarters	Q2 FY26 10-QJun 30, 2026
Puma Biotechnology	36,537	56,502	1,624*	51.6M	—	Q2 FY26 10-QJun 30, 2026
Eledon Pharmaceuticals	6,803	not reported	(22,677)*	81.3M	3.9 quarters	Q2 FY26 10-QJun 30, 2026
Voyager Therapeutics	35,769	3,165	(25,842)*	61.6M	4.5 quarters	Q2 FY26 10-QJun 30, 2026
Aclaris Therapeutics	19,167	1,629	(19,847)*	147.2M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Cognition	41,384	6,093	(6,859)*	21.8M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Sangamo Therapeutics	27,586	1,442	(19,282)	414.3M	1.4 quarters	Q1 FY26 10-QMar 31, 2026
Vistagen Therapeutics	16,991	not reported	(14,707)	44.4M	2.2 quarters	Q1 FY27 10-QJun 30, 2026
Monopar Therapeutics	52,758	0*	(3,247)*	6.7M	32.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.